The Zhitong Finance App learned that Zhaoke Ophthalmology-B (06622) rose by more than 3%. As of press release, it had risen 3.61% to HK$3.16, with a turnover of HK$1,140,900.
According to the news, Zhaoke Ophthalmology announced today that Zhaoke (Hong Kong) Ophthalmology Co., Ltd. (a wholly-owned subsidiary of the company) and Kwangdong PharmaceuticalCo. , Ltd. (KDP, a leading Korean company mainly engaged in pharmaceutical production and distribution) entered into a distribution and supply agreement for BRIMOCHOLPF (2.75% cabacol/ 0.1% bromonidine tartrate fixed dose compound) preservative-free topical eye drops (this product).
According to the terms of the agreement, the company has the right to grant KDP exclusive distribution rights for this product in Korea to obtain drug registration on behalf of the company and to exclusively import, promote, distribute, market and sell the product. The Company will collect a non-refundable and non-deductible advance payment and may receive additional milestone payments and royalties in accordance with certain regulatory achievements and product sales.